Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

por Yoshioka, T, Kato, S, Gamoh, M, Chiba, N, Suzuki, T, Sakayori, N, Kato, S, Shibata, H, Shimodaira, H, Otsuka, K, Kakudo, Y, Takahashi, S, Ishioka, C
Publicado 2009

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open...

por Yamada, Y, Denda, T, Gamoh, M, Iwanaga, I, Yuki, S, Shimodaira, H, Nakamura, M, Yamaguchi, T, Ohori, H, Kobayashi, K, Tsuda, M, Kobayashi, Y, Miyamoto, Y, Kotake, M, Shimada, K, Sato, A, Morita, S, Takahashi, S, Komatsu, Y, Ishioka, C
Publicado 2018

Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients

por Olivier, M, Langerød, A, Carrieri, P, Bergh, J, Klaar, S, Eyfjord, J, Theillet, C, Rodriguez, C, Lidereau, R, Bièche, I, Varley, J, Bignon, Y, Uhrhammer, N, Winqvist, R, Jukkola-Vuorinen, A, Niederacher, D, Kato, S, Ishioka, C, Hainaut, P, Børresen-Dale, A-L
Publicado 2005

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

por Yoshino, T., Cervantes, A., Bando, H., Martinelli, E., Oki, E., Xu, R.-H., Mulansari, N.A., Govind Babu, K., Lee, M.A., Tan, C.K., Cornelio, G., Chong, D.Q., Chen, L.-T., Tanasanvimon, S., Prasongsook, N., Yeh, K.-H., Chua, C., Sacdalan, M.D., Sow (Jenson), W.J., Kim, S.T., Chacko, R.T., Syaiful, R.A., Zhang, S.Z., Curigliano, G., Mishima, S., Nakamura, Y., Ebi, H., Sunakawa, Y., Takahashi, M., Baba, E., Peters, S., Ishioka, C., Pentheroudakis, G.
Publicado 2023